🩸🚀 New Insights in Liquid Biopsy! 🧬 The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis. 🔗 Read the full article here www.journalofliquidbiopsy.com/article/S295...

International Society of Liquid Biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors

Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing acc...

journalofliquidbiopsy.com

🚨Excited to represent the @islb.info at #ASCO25! Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities! Got questions about the society? We’ve got answers. Come to connect!🩸 @ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social

📍We proudly celebrate Prof. Christian Rolfo for being awarded the honorary title of Doctor Honoris Causa by the University of Buenos Aires! 🎓✨ Congratulations on this well-deserved recognition! @christianrolfo.bsky.social @yukselurun.bsky.social @mjoseserrano.bsky.social

Thank you, @christianrolfo.bsky.social! @swog.org #SWOGonc

Christian Rolfo@christianrolfo.bsky.social · last yr.

Thanks Hope Foundation SWOG for the great honor to give the Robert Livingston Translational Cancer Lecture. In memory of a pioneer in thoracic research.Thanks @JhanelleGray @DrRoyHerbstYale for the opportunity. @SupportingSWOG @OSUCCC_James @OhioStateMedOnc @OhioStateMedOnc

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx. ➡️ #Tepotinib showed robust efficacy regardless of biopsy type @christianrolfo.bsky.social @oncoalert.bsky.social

🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase  1B trial! ➡️12m OS 55 %  ➡️0 % ORR ➡️manageable safety profile @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala pmc.ncbi.nlm.nih.gov/articles/PMC...

Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?

pmc.ncbi.nlm.nih.gov

Thanks Hope Foundation SWOG for the great honor to give the Robert Livingston Translational Cancer Lecture. In memory of a pioneer in thoracic research.Thanks @JhanelleGray @DrRoyHerbstYale for the opportunity. @SupportingSWOG @OSUCCC_James @OhioStateMedOnc @OhioStateMedOnc

Today family picture with some of the 87 amazing faculty of our Division of Medical Oncology at The James CCC. Very honored to be part and lead this incredible team! @OhioStateMedOnc @OSUCCC_James @OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social

Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬 LB is reshaping cancer care 💥 Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/ @islb.info @christianrolfo.bsky.social @rolfolab.bsky.social

🚨We are hiring Medical Oncologists at @OhioStateMedOnc ! Check the QR code below for the available positions! 3 pathways: - Physician Scientist - Clinical Scholar - Clinical Excellence Send your applications @OSUCCC_James @OhioStateMed

Patients with #lungcancer enrolling to Lung-MAP can now be matched to a targeted treatment trial based on prior genomic testing, without submitting new tumor or blood samples, making Lung-MAP 3.0 accessible to more patients at a wider range of clinical sites. #lcsm www.swog.org/news-events/...

Make the most of your #AACR25 experience with in-person and virtual options, the AACR Runners for Research 5K Run/Walk, a performance by the CheckPoints, and more. Preview highlights in AACR Annual Meeting News: www.aacrmeetingnews.org/news/prepari...

Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬 Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social Exciting discussions shaping the future of #lungcancer testing! 📚

Congrats Roberto! And welcome to @rolfolab.bsky.social !!!

Roberto Borea MD@robertoboreamd.bsky.social · last yr.

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅 Grateful for the chance to meet with exceptional people 👐 @stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

🚨We are hiring Medical Oncologists at @OhioStateMedOnc ! Check the QR code below for the available positions! 3 pathways: - Physician Scientist - Clinical Scholar - Clinical Excellence Send your applications @OSUCCC_James @OhioStateMed

Navigating the future of #LiquidBiopsy with @christianrolfo.bsky.social at #poles25 From screening to resistance tracking—MRD is reshaping how we detect, treat, and monitor cancer. Tissue vs liquid? It’s not a battle—it’s a partnership. @rolfolab.bsky.social @islb.info @oncoalert.bsky.social

🎉🩸 Thrilled to share that the Journal of Liquid Biopsy is now officially live in PubMed and PMC! A significant step forward for JLB Check it out here: pmc.ncbi.nlm.nih.gov/journals/?te... #LiquidBiopsy #PubMed @christianrolfo.bsky.social @yukselurun.bsky.social @eloisajantus.bsky.social

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸 Read more: doi.org/10.1016/j.crit… #LiquidBiopsy @christianrolfo.bsky.social

🚨 Out in @natrevclinoncol.bsky.social 📌ctDNA helps uncover resistance mechanisms 📌Standardized protocols are crucial for improving applications 📌ctDNA + tissue provides a more comprehensive view nature.com/articles/s41... @christianrolfo.bsky.social @osucccjames.bsky.social

The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer! @christianrolfo.bsky.social @rolfolab.bsky.social @osucccjames.bsky.social #HER2 #IHC #Targettherapy

The OncoAlert Network 🚨@oncoalert.bsky.social · 2y ago

JOIN US for a discussion on HER2🧬testing & evolving role of IHC🔬 in hashtag#LungCancer & hashtag#OvarianCancer REGISTER HERE👇👇 buff.ly/7F6ztd4 JOIN US TUESDAY MARCH 11, 2025

Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬 --> bit.ly/3DFSzLi Panelists: @christianrolfo.bsky.social #UmbertoMalapelle #YasushiYatabe #MervatMahrous Organizer: #touchOncology @rolfolab.bsky.social @oncoalert.bsky.social

✨ Insightful presentation by @manelesteller.bsky.social from @carrerasijc.bsky.social at @osuwexmed.bsky.social Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊 @christianrolfo.bsky.social @rolfolab.bsky.social

⏱️ To-do list for today: Tune in to the live webinar by @iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs! @christianrolfo.bsky.social @rolfolab.bsky.social www.iaslc.org/meetings-web...

2024 Hot Topic in Basic & Translational Science Conference Highlights | IASLC

IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will ser ...

iaslc.org

Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊 #lungcancer #myESMO #DeepDiveLungCancer @christianrolfo.bsky.social @rolfolab.bsky.social ow.ly/vbSt50UPrrS

Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social

Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social

🎯 The ISLB created this survey to understand how to improve the use of #liquidbiopsy in clinical oncology! Don't miss the opportunity to shape the future of LB in cancer patients!! 🔥 @christianrolfo.bsky.social @robertoboreamd.bsky.social

The OncoAlert Network 🚨@oncoalert.bsky.social · 2y ago

Survey Participation Request on Behalf of @isliquidbiopsy & @OncoAlert Oncologist Attitudes and Practices on Liquid Biopsy 👉 https://buff.ly/3Cvf8BJ This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care.

OSU SABCS meeting - 200 participants in attendance. Great turn out and awesome presentations by our amazing Breast Cancer team. Very proud of them 🙂👏 @OhioStateMedOnc @StoverLab @quirogad @CherianMathew30 Maggie Gatti-Myes and all team! #SABCS24 @OSUCCC_James @OhioStateMed

Looking for your first faculty position? Or perhaps new start? THE Ohio State University Comprehensive Cancer Center (Columbus, OH) is hiring in several #MedOnc sections - GI, Thoracic, Breast, Neuroendocrine, cutaneous. #AcademicJobs #OSUCCC @osucccjames.bsky.social @christianrolfo.bsky.social